Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

DIXDC1 Promotes Lymphatic Metastasis and Resistance to Cuproptosis in Bladder Cancer Through Mediating DLAT.

Created on 28 Aug 2026

Authors

Hongqiong Li, Liang Cheng, Xiaole Lu, Haonan Dong, Shi Fu, Hongjin Shi, Mingsheng Liu, Chenwei Yang, Yuhang Huang, Zehua Chen, Yawei Zhang, Kaiwen Jie, Xiaoyue Zhang, Xiang Kui, Xinni Ye, Siting Chen, Xu Chen, Haifeng Wang

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e77435. Aug 27, 2026. Epub Aug 27, 2026.

Abstract

Lymph node metastasis (LN) represents a major clinical challenge in bladder cancer (BCa) and is associated with dismal prognosis; however, the underlying molecular drivers remain incompletely understood. Here, we demonstrate that DIX domain-containing protein 1 (DIXDC1) is significantly upregulated in LN-metastatic BCa tissues and is associated with unfavorable clinical outcomes. Functionally, DIXDC1 enhances BCa cell migration, invasion, proliferation, and lymph node dissemination in vivo. Mechanistically, DIXDC1 directly binds to dihydrolipoamide S-acetyltransferase (DLAT), a key enzyme in the tricarboxylic acid cycle and a central effector of cuproptosis. This interaction impedes ubiquitin-proteasome-mediated degradation of DLAT, thereby stabilizing DLAT protein levels. Through a DLAT-dependent pathway, DIXDC1 further augments the mRNA stability of the oncogenes NEK7 and CCNE2, fueling tumor progression. Importantly, DIXDC1 shields BCa cells from copper-induced DLAT oligomerization and confers marked resistance to Elesclomol-Cu (ES-Cu)-triggered cuproptosis. Depletion of DIXDC1 profoundly sensitizes tumors to cuproptosis in vivo. Collectively, our study unveils the DIXDC1-DLAT axis as a pivotal regulator that coordinately drives metastatic progression and suppresses copper-induced cell death, offering a promising therapeutic target for advanced BCa.

PMID:
42658569
Bibliographic data and abstract were imported from PubMed on 28 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement